73
© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Comprehensive Treatment Model Lowell C. Dale, MD Lowell C. Dale, MD Jon O. Ebbert, MD, MSc Jon O. Ebbert, MD, MSc Assistant Professors of Medicine Assistant Professors of Medicine Mayo Clinic College of Medicine Mayo Clinic College of Medicine Nicotine Dependence Center Nicotine Dependence Center

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

Embed Size (px)

Citation preview

Page 1: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Smokeless (Spit) Tobacco Use: Smokeless (Spit) Tobacco Use:

Comprehensive Treatment ModelComprehensive Treatment Model

Smokeless (Spit) Tobacco Use: Smokeless (Spit) Tobacco Use:

Comprehensive Treatment ModelComprehensive Treatment Model

Lowell C. Dale, MDLowell C. Dale, MD

Jon O. Ebbert, MD, MScJon O. Ebbert, MD, MSc

Assistant Professors of Medicine Assistant Professors of Medicine

Mayo Clinic College of MedicineMayo Clinic College of Medicine

Nicotine Dependence CenterNicotine Dependence Center

Lowell C. Dale, MDLowell C. Dale, MD

Jon O. Ebbert, MD, MScJon O. Ebbert, MD, MSc

Assistant Professors of Medicine Assistant Professors of Medicine

Mayo Clinic College of MedicineMayo Clinic College of Medicine

Nicotine Dependence CenterNicotine Dependence Center

Page 2: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Goals & ObjectivesGoals & ObjectivesGoals & ObjectivesGoals & Objectives

• Review ST definitions & productsReview ST definitions & products

• Discuss the prevalence of ST useDiscuss the prevalence of ST use

• Describe ST pharmacologyDescribe ST pharmacology

• Discuss ST dependence measures and Discuss ST dependence measures and withdrawalwithdrawal

• Review recommended treatments for ST useReview recommended treatments for ST use

• Review ST definitions & productsReview ST definitions & products

• Discuss the prevalence of ST useDiscuss the prevalence of ST use

• Describe ST pharmacologyDescribe ST pharmacology

• Discuss ST dependence measures and Discuss ST dependence measures and withdrawalwithdrawal

• Review recommended treatments for ST useReview recommended treatments for ST use

Page 3: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

ST Definitions & ProductsST Definitions & ProductsST Definitions & ProductsST Definitions & Products

Page 4: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Spit Tobacco - Definitions

• ““Smokeless” - industry termSmokeless” - industry term– Implies safetyImplies safety– Could be replaced with “spit”Could be replaced with “spit”

• Chewing tobaccoChewing tobacco– Loose leaf (i.e., Redman)Loose leaf (i.e., Redman)– PlugsPlugs– TwistsTwists

• SnuffSnuff– Moist (i.e., Copenhagen, Skoal)Moist (i.e., Copenhagen, Skoal)– Dry (i.e., Honest, Honey bee, Navy, Square)Dry (i.e., Honest, Honey bee, Navy, Square)

Page 5: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Smokeless Brand Used Most Often in Smokeless Brand Used Most Often in Last MonthLast Month

Smokeless Brand Used Most Often in Smokeless Brand Used Most Often in Last MonthLast Month

Col

umn

1

Column 2

Column 2 moist snuff chew dry snuff/other

Chart

Col

umn

1

Column 2

Column 2 moist snuff chew dry snuff/other

Chart

78.5%

National Household Survey on Drug Abuse, 2000

Page 6: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Preferred Snuff ProductsPreferred Snuff ProductsPreferred Snuff ProductsPreferred Snuff Products

Col

umn

1

Column 2

Column 2 Skoal Copenhagen Kodiak

Timber Wolf Red Seal Hawken

Silver Creek Rooster

Chart

Col

umn

1

Column 2

Column 2 Skoal Copenhagen Kodiak

Timber Wolf Red Seal Hawken

Silver Creek Rooster

Chart

National Household Survey on Drug Abuse, 2001

Page 7: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Chewing Tobacco ProductsChewing Tobacco ProductsChewing Tobacco ProductsChewing Tobacco Products

Col

umn

1

Column 2

Column 2 Red Man Beech Nut Levi Garrett

Apple Jack Blackbull Southern Pride

Chart

Col

umn

1

Column 2

Column 2 Red Man Beech Nut Levi Garrett

Apple Jack Blackbull Southern Pride

Chart

Page 8: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Prevalence of ST UsePrevalence of ST UsePrevalence of ST UsePrevalence of ST Use

Page 9: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Background - PrevalenceBackground - PrevalenceBackground - PrevalenceBackground - Prevalence

• In the U.S., 1991:In the U.S., 1991:• 5.3 million people regularly used ST5.3 million people regularly used ST

• By the year 2001, among individuals By the year 2001, among individuals >> 12 years of 12 years of age:age:

• 7.3 million regular ST users 7.3 million regular ST users [[Results from the 2001 National Household Survey Results from the 2001 National Household Survey

on Drug Abuse: Volume I. Summary of National Findingson Drug Abuse: Volume I. Summary of National Findings (Office of Applied Studies, NHSDA Series H-17, DHHS Publication No. (Office of Applied Studies, NHSDA Series H-17, DHHS Publication No. SMA 02-3758). Rockville, MD.]SMA 02-3758). Rockville, MD.]

• In the U.S., 1991:In the U.S., 1991:• 5.3 million people regularly used ST5.3 million people regularly used ST

• By the year 2001, among individuals By the year 2001, among individuals >> 12 years of 12 years of age:age:

• 7.3 million regular ST users 7.3 million regular ST users [[Results from the 2001 National Household Survey Results from the 2001 National Household Survey

on Drug Abuse: Volume I. Summary of National Findingson Drug Abuse: Volume I. Summary of National Findings (Office of Applied Studies, NHSDA Series H-17, DHHS Publication No. (Office of Applied Studies, NHSDA Series H-17, DHHS Publication No. SMA 02-3758). Rockville, MD.]SMA 02-3758). Rockville, MD.]

Page 10: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Background - PrevalenceBackground - PrevalenceBackground - PrevalenceBackground - Prevalence

• Among individuals Among individuals >> 12 years of age: 12 years of age:• 6.3% males6.3% males• 0.4% females0.4% females[[[[Results from the 2001 National Household Survey on Drug Abuse: Volume I. Summary of National FindingsResults from the 2001 National Household Survey on Drug Abuse: Volume I. Summary of National Findings (Office of (Office of

Applied Studies, NHSDA Series H-17, DHHS Publication No. SMA 02-3758). Rockville, MD.]Applied Studies, NHSDA Series H-17, DHHS Publication No. SMA 02-3758). Rockville, MD.]

• Highest rates of current ST use are found in American Highest rates of current ST use are found in American Indians and Alaska Natives.Indians and Alaska Natives.

• Northern Plains Native Americans: 25% prevalence of Northern Plains Native Americans: 25% prevalence of adult men adult men [USDHHS, 1998][USDHHS, 1998]

• Among individuals Among individuals >> 12 years of age: 12 years of age:• 6.3% males6.3% males• 0.4% females0.4% females[[[[Results from the 2001 National Household Survey on Drug Abuse: Volume I. Summary of National FindingsResults from the 2001 National Household Survey on Drug Abuse: Volume I. Summary of National Findings (Office of (Office of

Applied Studies, NHSDA Series H-17, DHHS Publication No. SMA 02-3758). Rockville, MD.]Applied Studies, NHSDA Series H-17, DHHS Publication No. SMA 02-3758). Rockville, MD.]

• Highest rates of current ST use are found in American Highest rates of current ST use are found in American Indians and Alaska Natives.Indians and Alaska Natives.

• Northern Plains Native Americans: 25% prevalence of Northern Plains Native Americans: 25% prevalence of adult men adult men [USDHHS, 1998][USDHHS, 1998]

Page 11: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Past Month Tobacco Use among Persons Past Month Tobacco Use among Persons Aged 12 or Older: 2001Aged 12 or Older: 2001

Past Month Tobacco Use among Persons Past Month Tobacco Use among Persons Aged 12 or Older: 2001Aged 12 or Older: 2001

Page 12: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Background - PrevalenceBackground - PrevalenceBackground - PrevalenceBackground - Prevalence

• ST use is higher in rural areas than in urban areas ST use is higher in rural areas than in urban areas [Centers for Disease [Centers for Disease

Control and Prevention, 1993 #1820]Control and Prevention, 1993 #1820]

• Use is reported to be higher in small towns than in large Use is reported to be higher in small towns than in large cities cities [Marcus, 1989 #909][Marcus, 1989 #909]

• The highest prevalence of ST use (after Alaska Natives) is The highest prevalence of ST use (after Alaska Natives) is found among:found among:

• White males between the ages of 18 and 25White males between the ages of 18 and 25• White males between the ages of 25 and 35 White males between the ages of 25 and 35 [Smith, 1999 #3][Smith, 1999 #3]

• ST use is higher in rural areas than in urban areas ST use is higher in rural areas than in urban areas [Centers for Disease [Centers for Disease

Control and Prevention, 1993 #1820]Control and Prevention, 1993 #1820]

• Use is reported to be higher in small towns than in large Use is reported to be higher in small towns than in large cities cities [Marcus, 1989 #909][Marcus, 1989 #909]

• The highest prevalence of ST use (after Alaska Natives) is The highest prevalence of ST use (after Alaska Natives) is found among:found among:

• White males between the ages of 18 and 25White males between the ages of 18 and 25• White males between the ages of 25 and 35 White males between the ages of 25 and 35 [Smith, 1999 #3][Smith, 1999 #3]

Page 13: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Background - PrevalenceBackground - PrevalenceBackground - PrevalenceBackground - Prevalence

• Among the population 12 years of age or older who had used Among the population 12 years of age or older who had used ST in the last month:ST in the last month:

• 0.8% of the Hispanic population 0.8% of the Hispanic population • 1.3% among Hispanic males1.3% among Hispanic males

• 2.0% of the African-Americans2.0% of the African-Americans• 2% among African-American males2% among African-American males

• 0.2% among women 0.2% among women [NHSDA, 1998].[NHSDA, 1998].

• 1.3% among women attending college 1.3% among women attending college [Rigotti, 2000][Rigotti, 2000]

• Among the population 12 years of age or older who had used Among the population 12 years of age or older who had used ST in the last month:ST in the last month:

• 0.8% of the Hispanic population 0.8% of the Hispanic population • 1.3% among Hispanic males1.3% among Hispanic males

• 2.0% of the African-Americans2.0% of the African-Americans• 2% among African-American males2% among African-American males

• 0.2% among women 0.2% among women [NHSDA, 1998].[NHSDA, 1998].

• 1.3% among women attending college 1.3% among women attending college [Rigotti, 2000][Rigotti, 2000]

Page 14: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Background - Marketing & SalesBackground - Marketing & SalesBackground - Marketing & SalesBackground - Marketing & Sales

• In 2001:In 2001:

• Advertising & Promotion = Advertising & Promotion = $236.7 million$236.7 million

• Amount sold = Amount sold = 112 million pounds112 million pounds

• Sales revenues = Sales revenues = $2.13 billion in 2001$2.13 billion in 2001

[Federal Trade Commission, 2001-3][Federal Trade Commission, 2001-3]

• In 2001:In 2001:

• Advertising & Promotion = Advertising & Promotion = $236.7 million$236.7 million

• Amount sold = Amount sold = 112 million pounds112 million pounds

• Sales revenues = Sales revenues = $2.13 billion in 2001$2.13 billion in 2001

[Federal Trade Commission, 2001-3][Federal Trade Commission, 2001-3]

Page 15: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Adverse Health EffectsAdverse Health EffectsAdverse Health EffectsAdverse Health Effects

Page 16: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Smokeless Tobacco - Health Smokeless Tobacco - Health Consequences Consequences

Smokeless Tobacco - Health Smokeless Tobacco - Health Consequences Consequences

Report on Carcinogens, 10th Edition, National Report on Carcinogens, 10th Edition, National Toxicology Program, USDHHSToxicology Program, USDHHS

Smokeless tobaccoSmokeless tobacco

““Known to be a human carcinogen”Known to be a human carcinogen”

Report on Carcinogens, 10th Edition, National Report on Carcinogens, 10th Edition, National Toxicology Program, USDHHSToxicology Program, USDHHS

Smokeless tobaccoSmokeless tobacco

““Known to be a human carcinogen”Known to be a human carcinogen”

Page 17: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

ST - Health Consequences ST - Health Consequences ST - Health Consequences ST - Health Consequences

• CarcinogensCarcinogens

• AldehydesAldehydes

• Tobacco-specific N-nitrosamines (TSNAs)Tobacco-specific N-nitrosamines (TSNAs)• 7 types identified7 types identified

• Polycyclic aromatic hydrocarbonsPolycyclic aromatic hydrocarbons

• Polonium 210Polonium 210

• CarcinogensCarcinogens

• AldehydesAldehydes

• Tobacco-specific N-nitrosamines (TSNAs)Tobacco-specific N-nitrosamines (TSNAs)• 7 types identified7 types identified

• Polycyclic aromatic hydrocarbonsPolycyclic aromatic hydrocarbons

• Polonium 210Polonium 210

Page 18: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

ST - Health ConsequencesST - Health Consequences

• Risk appears to be different in different parts of world

• Likely relates to the type of ST use

• U.S. - Snuff & chewing tobacco

• Scandinavia - snus (lower levels of TSNAs)

• India - mixed with more carcingens (i.e., betel)

• Africa - “toombak” (I.e., N. rustica + Na bicarbonate)

• Risk appears to be different in different parts of world

• Likely relates to the type of ST use

• U.S. - Snuff & chewing tobacco

• Scandinavia - snus (lower levels of TSNAs)

• India - mixed with more carcingens (i.e., betel)

• Africa - “toombak” (I.e., N. rustica + Na bicarbonate)

Page 19: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Health Effects of ST: Systematic ReviewHealth Effects of ST: Systematic Review

• Electronic database search, references lists, smoking-related websites, and contacted experts

• Observational studies of ST use with > 500 subjects• Cohorts• Case-control• Cross sectional studies

• Electronic database search, references lists, smoking-related websites, and contacted experts

• Observational studies of ST use with > 500 subjects• Cohorts• Case-control• Cross sectional studies

Critchley et al. Thorax. 2003; 58: 435-443.

Page 20: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

SR: Oral and Pharyngeal Cancers - U.S. DataSR: Oral and Pharyngeal Cancers - U.S. Data

Location OR (95% CI)

Cancer, Mouth and Gum 11.2 (4.1-30.7)A

Gum & Buccal Mucosa 4.2 (2.6-6.7)B

Larynx 7.3 (2.9-18.3)A

Salivary gland 5.3 (1.2-23.4)A

Location OR (95% CI)

Cancer, Mouth and Gum 11.2 (4.1-30.7)A

Gum & Buccal Mucosa 4.2 (2.6-6.7)B

Larynx 7.3 (2.9-18.3)A

Salivary gland 5.3 (1.2-23.4)A

A - Stockwell et al, 1986

B- Winn et al., 1981

Page 21: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

SR: Oral and Pharyngeal Cancers - U.S. DataSR: Oral and Pharyngeal Cancers - U.S. Data

Winn et al., 1981

Cancer of gum and buccal mucosa = dose responseCancer of gum and buccal mucosa = dose response

> 50 years> 50 years

OR = 47.5 (95% CI: 9.1-249.5)OR = 47.5 (95% CI: 9.1-249.5)

1-24 years1-24 years: :

OR = 13.8 (95% CI: 1.9 to 98.0)OR = 13.8 (95% CI: 1.9 to 98.0)

Page 22: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

SR: Cancer Other Sites - U.S. DataSR: Cancer Other Sites - U.S. Data

Location OR (95% CI)

Bladder 4.0 (1.1-14.2)

Location OR (95% CI)

Bladder 4.0 (1.1-14.2)

Goodman et al., 1986

Page 23: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

SR: Cardiovascular Disease - ScandinaviaSR: Cardiovascular Disease - Scandinavia

• Current/exclusive use compared w/ never smokers

• 35-54 year olds: • Ischemic heart disease: RR 2.0 (95% CI: 1.49-2.9)• Cardiovascular death: RR 2.1 (95% CI: 1.5-2.9)

• 55-64 year olds:• IHD: RR 1.2 (95% CI: 1.0-1.5)• CVD: RR 1.1 (95% CI: 1.0-1.4)

• Current/exclusive use compared w/ never smokers

• 35-54 year olds: • Ischemic heart disease: RR 2.0 (95% CI: 1.49-2.9)• Cardiovascular death: RR 2.1 (95% CI: 1.5-2.9)

• 55-64 year olds:• IHD: RR 1.2 (95% CI: 1.0-1.5)• CVD: RR 1.1 (95% CI: 1.0-1.4)

Bolinder et al., 1994

Page 24: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

SR: Dental Disease - U.S. DataSR: Dental Disease - U.S. Data

• Dental disease = caries & periodontal disease

• Decayed root surfaces: OR 3.24 (95% CI: 2.0-4.4)A

• Periodontal disease:

• Attachment loss more common in ST users without oral lesions than non-users (33.6% vs. 27.4%, P < 0.05)B

• Dental disease = caries & periodontal disease

• Decayed root surfaces: OR 3.24 (95% CI: 2.0-4.4)A

• Periodontal disease:

• Attachment loss more common in ST users without oral lesions than non-users (33.6% vs. 27.4%, P < 0.05)B

A - Tomar et al., 1999

B - Ernster et al., 1990

Page 25: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

SR: Oral Cancer Deaths……… SR: Oral Cancer Deaths………

Critchley et al., 2003

Location, Location, Location

Page 26: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

ST - Oral LesionsST - Oral LesionsST - Oral LesionsST - Oral Lesions

• LeukoplakiaLeukoplakia

• ErythroleukoplakiaErythroleukoplakia

• Oral cancerOral cancer

• Dental diseaseDental disease• erosion of enamelerosion of enamel• dental cariesdental caries

• Periodontal DiseasePeriodontal Disease• gingival recessiongingival recession• soft tissue/hard tissue losssoft tissue/hard tissue loss• gingivitisgingivitis

• LeukoplakiaLeukoplakia

• ErythroleukoplakiaErythroleukoplakia

• Oral cancerOral cancer

• Dental diseaseDental disease• erosion of enamelerosion of enamel• dental cariesdental caries

• Periodontal DiseasePeriodontal Disease• gingival recessiongingival recession• soft tissue/hard tissue losssoft tissue/hard tissue loss• gingivitisgingivitis

Page 27: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

ST - Oral LesionsST - Oral LesionsST - Oral LesionsST - Oral Lesions

• LeukoplakiaLeukoplakia

• ErythroleukoplakiaErythroleukoplakia

• Oral cancerOral cancer

• Dental diseaseDental disease• erosion of enamelerosion of enamel• dental cariesdental caries

• Periodontal DiseasePeriodontal Disease• gingival recessiongingival recession• soft tissue/hard tissue losssoft tissue/hard tissue loss• gingivitisgingivitis

• LeukoplakiaLeukoplakia

• ErythroleukoplakiaErythroleukoplakia

• Oral cancerOral cancer

• Dental diseaseDental disease• erosion of enamelerosion of enamel• dental cariesdental caries

• Periodontal DiseasePeriodontal Disease• gingival recessiongingival recession• soft tissue/hard tissue losssoft tissue/hard tissue loss• gingivitisgingivitis

Page 28: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

ST - Oral LesionsST - Oral LesionsST - Oral LesionsST - Oral Lesions

• LeukoplakiaLeukoplakia

• ErythroleukoplakiaErythroleukoplakia

• Oral cancerOral cancer

• Dental diseaseDental disease• erosion of enamelerosion of enamel• dental cariesdental caries

• Periodontal DiseasePeriodontal Disease• gingival recessiongingival recession• soft tissue/hard tissue losssoft tissue/hard tissue loss• gingivitisgingivitis

• LeukoplakiaLeukoplakia

• ErythroleukoplakiaErythroleukoplakia

• Oral cancerOral cancer

• Dental diseaseDental disease• erosion of enamelerosion of enamel• dental cariesdental caries

• Periodontal DiseasePeriodontal Disease• gingival recessiongingival recession• soft tissue/hard tissue losssoft tissue/hard tissue loss• gingivitisgingivitis

Page 29: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

ST - Oral LesionsST - Oral LesionsST - Oral LesionsST - Oral Lesions

• LeukoplakiaLeukoplakia

• ErythroleukoplakiaErythroleukoplakia

• Oral cancerOral cancer

• Dental diseaseDental disease• erosion of enamelerosion of enamel• dental cariesdental caries

• Periodontal DiseasePeriodontal Disease• gingival recessiongingival recession• soft tissue/hard tissue losssoft tissue/hard tissue loss• gingivitisgingivitis

• LeukoplakiaLeukoplakia

• ErythroleukoplakiaErythroleukoplakia

• Oral cancerOral cancer

• Dental diseaseDental disease• erosion of enamelerosion of enamel• dental cariesdental caries

• Periodontal DiseasePeriodontal Disease• gingival recessiongingival recession• soft tissue/hard tissue losssoft tissue/hard tissue loss• gingivitisgingivitis

Page 30: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

ST - Oral LesionsST - Oral LesionsST - Oral LesionsST - Oral Lesions

• LeukoplakiaLeukoplakia

• ErythroleukoplakiaErythroleukoplakia

• Oral cancerOral cancer

• Dental diseaseDental disease• erosion of enamelerosion of enamel• dental cariesdental caries

• Periodontal DiseasePeriodontal Disease• gingival recessiongingival recession• soft tissue/hard tissue losssoft tissue/hard tissue loss• gingivitisgingivitis

• LeukoplakiaLeukoplakia

• ErythroleukoplakiaErythroleukoplakia

• Oral cancerOral cancer

• Dental diseaseDental disease• erosion of enamelerosion of enamel• dental cariesdental caries

• Periodontal DiseasePeriodontal Disease• gingival recessiongingival recession• soft tissue/hard tissue losssoft tissue/hard tissue loss• gingivitisgingivitis

Page 31: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

ST PharmacologyST PharmacologyST PharmacologyST Pharmacology

Page 32: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Smokeless Tobacco PharmacologySmokeless Tobacco PharmacologySmokeless Tobacco PharmacologySmokeless Tobacco Pharmacology

• Potential available nicotine is twice that obtained from Potential available nicotine is twice that obtained from smoking a cigarette:smoking a cigarette:

chewing tobaccochewing tobacco 4.5 mg4.5 mg

moist snuffmoist snuff 3.6 mg3.6 mg

4 mg nicotine gum4 mg nicotine gum 1.9 mg1.9 mg

cigarettecigarette 1.8 mg 1.8 mg

• Potential available nicotine is twice that obtained from Potential available nicotine is twice that obtained from smoking a cigarette:smoking a cigarette:

chewing tobaccochewing tobacco 4.5 mg4.5 mg

moist snuffmoist snuff 3.6 mg3.6 mg

4 mg nicotine gum4 mg nicotine gum 1.9 mg1.9 mg

cigarettecigarette 1.8 mg 1.8 mg

Page 33: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Smokeless Tobacco PharmacologySmokeless Tobacco PharmacologySmokeless Tobacco PharmacologySmokeless Tobacco Pharmacology

4.8 mg nicotine/gm of moist snuff x 30 gm/can = 144 mg4.8 mg nicotine/gm of moist snuff x 30 gm/can = 144 mg

144 mg nicotine/(1.8 mg nicotine/cigarette) = 80 cigarettes144 mg nicotine/(1.8 mg nicotine/cigarette) = 80 cigarettes

80 cigarettes/(20 cigarettes/pack) = 4 packs80 cigarettes/(20 cigarettes/pack) = 4 packs

1 can snuff = 4 packs of cigarettes1 can snuff = 4 packs of cigarettes

3 cans/day = As much nicotine as 12 packs of cigarettes3 cans/day = As much nicotine as 12 packs of cigarettes

Page 34: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Smokeless Tobacco PharmacologySmokeless Tobacco PharmacologySmokeless Tobacco PharmacologySmokeless Tobacco Pharmacology

• Slower absorption than with smokingSlower absorption than with smoking

• Peak concentration at 30 minutesPeak concentration at 30 minutes

• Persistent absorption for up to 60 minutes after Persistent absorption for up to 60 minutes after tobacco removedtobacco removed

• slow release from mucous membranesslow release from mucous membranes• absorption of swallowed nicotineabsorption of swallowed nicotine

• Slower absorption than with smokingSlower absorption than with smoking

• Peak concentration at 30 minutesPeak concentration at 30 minutes

• Persistent absorption for up to 60 minutes after Persistent absorption for up to 60 minutes after tobacco removedtobacco removed

• slow release from mucous membranesslow release from mucous membranes• absorption of swallowed nicotineabsorption of swallowed nicotine

Page 35: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Smokeless Tobacco PharmacologySmokeless Tobacco PharmacologySmokeless Tobacco PharmacologySmokeless Tobacco Pharmacology

Blo

od

nic

oti n

e c

on

cen

t ra

ti on

(ng

/ml)

Benowitz, NL et al. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 1988; 44: 23-8.Benowitz et al, 1988.

Page 36: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Page 37: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVEDBenowitz et al, 1989.

Page 38: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

ST Characteristics Affecting Nicotine Blood LevelsST Characteristics Affecting Nicotine Blood LevelsST Characteristics Affecting Nicotine Blood LevelsST Characteristics Affecting Nicotine Blood Levels

• Concentration of nicotine in ST productConcentration of nicotine in ST product

• Size of the tobacco cuttingsSize of the tobacco cuttings• Long cutLong cut• Fine cut (higher)Fine cut (higher)

• Lower acid level of product - higher free nicotineLower acid level of product - higher free nicotine

• Concentration of nicotine in ST productConcentration of nicotine in ST product

• Size of the tobacco cuttingsSize of the tobacco cuttings• Long cutLong cut• Fine cut (higher)Fine cut (higher)

• Lower acid level of product - higher free nicotineLower acid level of product - higher free nicotine

Page 39: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVEDCDC, 1999.

Free Nicotine as a Function of pH

Page 40: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

UST’s “graduation strategy” in a UST document exhibited in the Marsee vs US Tobacco Company Lawsuit, 1986

UST’s “graduation strategy” in a UST document exhibited in the Marsee vs US Tobacco Company Lawsuit, 1986

Connolly, G. N. (1995). “The marketing of nicotine addiction by one oral snuff manufacturer.” Tob Control 4: 73-79.

Page 41: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Fant, RV et al. Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tobacco Control 1999; 8: 387-392.

Impact of pH ManipulationImpact of pH Manipulation

Page 42: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Impact of pH ManipulationImpact of pH Manipulation

• Likelihood of choosing a brand with higher nicotine content is related to:

• Increasing duration of use• Increasing intensity of use• Frequency of ST use [Tomar, 1995 #2892]

• ST users who have used higher nicotine-containing products are more likely to report:

• More nicotine withdrawal symptoms• Continued use because of difficulty quitting

• Likelihood of choosing a brand with higher nicotine content is related to:

• Increasing duration of use• Increasing intensity of use• Frequency of ST use [Tomar, 1995 #2892]

• ST users who have used higher nicotine-containing products are more likely to report:

• More nicotine withdrawal symptoms• Continued use because of difficulty quitting

Tomar, S. L., G. A. Giovino, et al. (1995). “Smokeless tobacco brand preference and brand switching among US adolescents and young adults.” Tob Control 4: 67-72.

Page 43: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

ST Dependence & WithdrawalST Dependence & WithdrawalST Dependence & WithdrawalST Dependence & Withdrawal

Page 44: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Frequency of Withdrawal Symptoms in 162 ST UsersFrequency of Withdrawal Symptoms in 162 ST UsersFrequency of Withdrawal Symptoms in 162 ST UsersFrequency of Withdrawal Symptoms in 162 ST Users

0%

10%

20%

30%

40%

50%

60%

70%

CravingIrritabilityIncreased eatingAnxietyImpatienceRestlessnessDepressed moodDifficulty concentratingDisrupted sleep

0%

10%

20%

30%

40%

50%

60%

70%

CravingIrritabilityIncreased eatingAnxietyImpatienceRestlessnessDepressed moodDifficulty concentratingDisrupted sleep

Ebbert et al.

Page 45: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Measuring Dependence in ST UsersMeasuring Dependence in ST UsersMeasuring Dependence in ST UsersMeasuring Dependence in ST Users

• Predictors of nicotine dependence (modified FTQ)Predictors of nicotine dependence (modified FTQ)

• Using ST within 30 minutes of waking upUsing ST within 30 minutes of waking up• Higher number of tins per weekHigher number of tins per week• Always swallowing tobacco juiceAlways swallowing tobacco juice

• Predictors of nicotine dependence (modified FTQ)Predictors of nicotine dependence (modified FTQ)

• Using ST within 30 minutes of waking upUsing ST within 30 minutes of waking up• Higher number of tins per weekHigher number of tins per week• Always swallowing tobacco juiceAlways swallowing tobacco juice

Boyle et al. Addictive Behaviors. Vol. 20, No. 4, pp. 443-450. 1995

Page 46: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Measuring Dependence in ST UsersMeasuring Dependence in ST UsersMeasuring Dependence in ST UsersMeasuring Dependence in ST Users

• Predictors of nicotine dependence (modified FTQ)Predictors of nicotine dependence (modified FTQ)

• Using ST within 30 minutes of waking upUsing ST within 30 minutes of waking up• Higher number of tins per weekHigher number of tins per week• Always swallowing tobacco juiceAlways swallowing tobacco juice• Using in inappropriate placesUsing in inappropriate places

• Church, synagogue, mosqueChurch, synagogue, mosque• Using ST when ill in bedUsing ST when ill in bed• Nicotine contentNicotine content

• Copenhagen > Skoal banditsCopenhagen > Skoal bandits• Chewing more in the morning Chewing more in the morning • Morning chews are harder to give upMorning chews are harder to give up• Chewing more than 16 hours/dayChewing more than 16 hours/day

• Predictors of nicotine dependence (modified FTQ)Predictors of nicotine dependence (modified FTQ)

• Using ST within 30 minutes of waking upUsing ST within 30 minutes of waking up• Higher number of tins per weekHigher number of tins per week• Always swallowing tobacco juiceAlways swallowing tobacco juice• Using in inappropriate placesUsing in inappropriate places

• Church, synagogue, mosqueChurch, synagogue, mosque• Using ST when ill in bedUsing ST when ill in bed• Nicotine contentNicotine content

• Copenhagen > Skoal banditsCopenhagen > Skoal bandits• Chewing more in the morning Chewing more in the morning • Morning chews are harder to give upMorning chews are harder to give up• Chewing more than 16 hours/dayChewing more than 16 hours/day

Boyle et al. Addictive Behaviors. Vol. 20, No. 4, pp. 443-450. 1995

Page 47: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Current Recommendations for Current Recommendations for TreatmentTreatment

Current Recommendations for Current Recommendations for TreatmentTreatment

Page 48: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Methods of Treating Smokeless Tobacco UseMethods of Treating Smokeless Tobacco UseMethods of Treating Smokeless Tobacco UseMethods of Treating Smokeless Tobacco Use

Behavioral

Pharmacologic

Page 49: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Literature ReviewLiterature ReviewLiterature ReviewLiterature Review

• ““What interventions are effective for ST users?”What interventions are effective for ST users?”

• Two systematic reviews of treatment:Two systematic reviews of treatment:• Ebbert, J. O., L. C. Rowland, et al. (2003). Ebbert, J. O., L. C. Rowland, et al. (2003).

“Treatments for spit tobacco use: a “Treatments for spit tobacco use: a quantitative systematic review.” quantitative systematic review.” AddictionAddiction 9898(5): 569-83.(5): 569-83.

• Severson, H. H. (2003). “What have we Severson, H. H. (2003). “What have we learned from 20 years of research on learned from 20 years of research on smokeless tobacco cessation?” smokeless tobacco cessation?” Am J Med Am J Med SciSci 326326(4): 206-11.(4): 206-11.

• ““What interventions are effective for ST users?”What interventions are effective for ST users?”

• Two systematic reviews of treatment:Two systematic reviews of treatment:• Ebbert, J. O., L. C. Rowland, et al. (2003). Ebbert, J. O., L. C. Rowland, et al. (2003).

“Treatments for spit tobacco use: a “Treatments for spit tobacco use: a quantitative systematic review.” quantitative systematic review.” AddictionAddiction 9898(5): 569-83.(5): 569-83.

• Severson, H. H. (2003). “What have we Severson, H. H. (2003). “What have we learned from 20 years of research on learned from 20 years of research on smokeless tobacco cessation?” smokeless tobacco cessation?” Am J Med Am J Med SciSci 326326(4): 206-11.(4): 206-11.

Page 50: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Literature Review: ConclusionsLiterature Review: ConclusionsLiterature Review: ConclusionsLiterature Review: Conclusions

Severson, H. H. (2003). “What have we learned from 20 years of research on smokeless tobacco cessation?” Am J Med Sci 326(4): 206-11.

Severson, H. H. (2003). “What have we learned from 20 years of research on smokeless tobacco cessation?” Am J Med Sci 326(4): 206-11.

Page 51: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Literature Review: ConclusionsLiterature Review: ConclusionsLiterature Review: ConclusionsLiterature Review: Conclusions

• Meta-analyses:Meta-analyses:

• Behavioral interventions Behavioral interventions areare effective. effective.• Bupropion SR Bupropion SR is probablyis probably effective intervention effective intervention

for ST users. for ST users. • NRT NRT may bemay be an effective intervention for ST an effective intervention for ST

users.users.• Among the behavioral interventions, the use of an Among the behavioral interventions, the use of an

oral examination appears to be associated with oral examination appears to be associated with the greatest treatment effect.the greatest treatment effect.

• Meta-analyses:Meta-analyses:

• Behavioral interventions Behavioral interventions areare effective. effective.• Bupropion SR Bupropion SR is probablyis probably effective intervention effective intervention

for ST users. for ST users. • NRT NRT may bemay be an effective intervention for ST an effective intervention for ST

users.users.• Among the behavioral interventions, the use of an Among the behavioral interventions, the use of an

oral examination appears to be associated with oral examination appears to be associated with the greatest treatment effect.the greatest treatment effect.

Ebbert, J. O., L. C. Rowland, et al. (2003). “Treatments for spit tobacco use: a quantitative systematic review.” Ebbert, J. O., L. C. Rowland, et al. (2003). “Treatments for spit tobacco use: a quantitative systematic review.” AddictionAddiction 9898(5): 569-83.(5): 569-83.

Page 52: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Pharmacologic TreatmentPharmacologic Treatment::

Nicotine Patch Percentage Nicotine Patch Percentage ReplacementReplacement

Pharmacologic TreatmentPharmacologic Treatment::

Nicotine Patch Percentage Nicotine Patch Percentage ReplacementReplacement

Page 53: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVEDDale, et al. JAMA, 1995.

Page 54: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Peak serumPeak serumnicotinenicotine

concentrationsconcentrations(ng/mL)(ng/mL)

Cans or pouchesCans or pouchesper weekper week Patch dosePatch dose

LowLow 0-100-10 = 1= 1 14 mg/d14 mg/d

IntermediateIntermediate 11-2011-20 2-32-3 21or 22 mg/d21or 22 mg/d

HighHigh > 20> 20 > 3> 3 42 or 44 mg/d42 or 44 mg/d

NRT for ST Users

Page 55: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Recommended ST Treatment ApproachRecommended ST Treatment ApproachRecommended ST Treatment ApproachRecommended ST Treatment Approach

1) Behavioral treatment1) Behavioral treatment• Oral examinationOral examination• +/- oral replacement products+/- oral replacement products

2) Bupropion2) Bupropion• 150 mg po qd x 3 days then bid150 mg po qd x 3 days then bid• Quit 1 week laterQuit 1 week later• Continue for 3-6 monthsContinue for 3-6 months

3) Tailored nicotine patch therapy3) Tailored nicotine patch therapy• +/- gum/lozenge for self-titration+/- gum/lozenge for self-titration

1) Behavioral treatment1) Behavioral treatment• Oral examinationOral examination• +/- oral replacement products+/- oral replacement products

2) Bupropion2) Bupropion• 150 mg po qd x 3 days then bid150 mg po qd x 3 days then bid• Quit 1 week laterQuit 1 week later• Continue for 3-6 monthsContinue for 3-6 months

3) Tailored nicotine patch therapy3) Tailored nicotine patch therapy• +/- gum/lozenge for self-titration+/- gum/lozenge for self-titration

Page 56: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Oral ExamOral Exam

• Oral exam .pdf available at:

• http://www.nohic.nidcr.nih.gov/pdfs/OralPoster2002.pdf

• Oral exam .pdf available at:

• http://www.nohic.nidcr.nih.gov/pdfs/OralPoster2002.pdf

Page 57: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Nicotine LozengeNicotine Lozenge

• Nicotine Polacrilex•2 mg•4 mg

• Dissolves in mouth over 20-30 minutes

• Delivers 25% more nicotine than the gum

• Nicotine Polacrilex•2 mg•4 mg

• Dissolves in mouth over 20-30 minutes

• Delivers 25% more nicotine than the gum

Page 58: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Nicotine LozengeDosing

Nicotine LozengeDosing

• 1-2 lozenges every 1-2 hours

• Minimum of 9/day

• Taper over 12 weeks

• 1-2 lozenges every 1-2 hours

• Minimum of 9/day

• Taper over 12 weeks

Page 59: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Nicotine LozengeSide-Effects

Nicotine LozengeSide-Effects

• Nausea (12-15%)

• Heartburn (5-6%)

• Hiccups (3-8%)

• Not to be chewed or swallowed whole

• Avoid eating or drinking food during and 15 minutes prior to use

• Nausea (12-15%)

• Heartburn (5-6%)

• Hiccups (3-8%)

• Not to be chewed or swallowed whole

• Avoid eating or drinking food during and 15 minutes prior to use

Page 60: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Nicotine GumNicotine Gum

• Useful adjunct with interventionUseful adjunct with intervention

• Most effective with counselingMost effective with counseling

• 2 mg and 4 mg2 mg and 4 mg

• ““Chew and Park”Chew and Park”

• Frequent use initially (10-15/day)Frequent use initially (10-15/day)

• Often used in combination with other NRTOften used in combination with other NRT

Page 61: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Nicotine GumNicotine Gum: Side EffectsNicotine GumNicotine Gum: Side Effects

• mouth soreness

• hiccups

• stomach upset/nausea

• jaw aches

• mouth soreness

• hiccups

• stomach upset/nausea

• jaw aches

Page 62: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Bupropion SRBupropion SRDosing

Bupropion SRBupropion SRDosing

150 mg daily for 3-4 days

then

150 mg twice a day for 3-4 days

THEN

STOP Tobacco

150 mg daily for 3-4 days

then

150 mg twice a day for 3-4 days

THEN

STOP Tobacco

Page 63: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

BupropionBupropionSide EffectsSide Effects

BupropionBupropionSide EffectsSide Effects

• Insomnia (35%)

• Dry mouth (13%)

• Anxiety (5%)

• Rash (2%)

• Seizures: 1/1000

• Insomnia (35%)

• Dry mouth (13%)

• Anxiety (5%)

• Rash (2%)

• Seizures: 1/1000

Page 64: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

BupropionBupropionSeizure Risk

BupropionBupropionSeizure Risk

• History of seizures

• Previous head/CNS trauma

• Eating disorders (bulimia/anorexia nervosa)

• Neuroleptic medications

• High doses of Bupropion

• History of seizures

• Previous head/CNS trauma

• Eating disorders (bulimia/anorexia nervosa)

• Neuroleptic medications

• High doses of Bupropion

Page 65: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Bupropion SRBupropion SRDosing

Bupropion SRBupropion SRDosing

• Duration: 8-12 weeks

• Safe to use longer

• Taper is unnecessary

• Combination with NRT

• Duration: 8-12 weeks

• Safe to use longer

• Taper is unnecessary

• Combination with NRT

Page 66: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

• Pilot projectPilot project

• 8-day inpatient program8-day inpatient program

• Didactics, group therapy/individual therapyDidactics, group therapy/individual therapy

• Tailored pharmacotherapyTailored pharmacotherapy

• Combination (bupropion & NRT)Combination (bupropion & NRT)

• Percentage replacementPercentage replacement

• Dental hygienist visit and a dental examination with Dental hygienist visit and a dental examination with

photographs of suspicious lesions.photographs of suspicious lesions.

Residential Treatment Program

Page 67: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

• 3-month self-reported continuous abstinence rate:3-month self-reported continuous abstinence rate:

• 22/24 = 92%22/24 = 92%

• 6-month self-reported continuous abstinence rate:6-month self-reported continuous abstinence rate:

• 21/24 = 88%21/24 = 88%

• 12-month 12-month biochemically-confirmedbiochemically-confirmed point prevalence point prevalence

tobacco abstinence rate:tobacco abstinence rate:

• 12/24 = 50%12/24 = 50%

Results

Page 68: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

“Paul”“Paul”

• 34 years old

• Spit tobacco for 28 years

• Now: Copenhagen 1 tin/day

• Quit attempts: 4-5, longest 2 days

• Exam: plaque, supragingival calculus, erythema and inflamed tissue, areas of leukoplakia on the labial vestibule opposite lower incisors

• 34 years old

• Spit tobacco for 28 years

• Now: Copenhagen 1 tin/day

• Quit attempts: 4-5, longest 2 days

• Exam: plaque, supragingival calculus, erythema and inflamed tissue, areas of leukoplakia on the labial vestibule opposite lower incisors

Page 69: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

“Paul”“Paul”

• Nicotine Level: 40 ng/ml

• Cotinine Level: 402 ng/ml

• Treatment: • Bupropion SR 150 bid• Residential Program• 42 mg nicotine patch• Nicotine gum as needed• Snuff substitute as needed

• Nicotine Level: 40 ng/ml

• Cotinine Level: 402 ng/ml

• Treatment: • Bupropion SR 150 bid• Residential Program• 42 mg nicotine patch• Nicotine gum as needed• Snuff substitute as needed

Page 70: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

“Paul”“Paul”

• Day 2: Difficulty sleeping, strong cravings, constantly thinking about Copenhagen. Using mint snuff oral substitute.

• Plan: Increase to 56 mg nicotine patch/day

• Day 2: Difficulty sleeping, strong cravings, constantly thinking about Copenhagen. Using mint snuff oral substitute.

• Plan: Increase to 56 mg nicotine patch/day

Page 71: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

“Paul”“Paul”

• Day 4: Slept much better. Significant decrease in cravings. Continues with snuff substitute.

• Nicotine level: 37 ng/ml

• Cotinine level: 318 ng/ml

• Day 4: Slept much better. Significant decrease in cravings. Continues with snuff substitute.

• Nicotine level: 37 ng/ml

• Cotinine level: 318 ng/ml

Page 72: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

“Paul”“Paul”

• Day 8: Dismiss on 56mg/day nicotine patch for 4 weeks and then taper as tolerated; bupropion SR 150 bid for at least 3 months. Follow-up with counselor regularly by telephone.

• Day 8: Dismiss on 56mg/day nicotine patch for 4 weeks and then taper as tolerated; bupropion SR 150 bid for at least 3 months. Follow-up with counselor regularly by telephone.

Page 73: © 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,

© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED

Goals & ObjectivesGoals & ObjectivesGoals & ObjectivesGoals & Objectives

• Review ST definitions & productsReview ST definitions & products

• Discuss the prevalence of ST useDiscuss the prevalence of ST use

• Describe ST pharmacologyDescribe ST pharmacology

• Discuss ST dependence measures and Discuss ST dependence measures and withdrawalwithdrawal

• Review recommended treatments for ST useReview recommended treatments for ST use

• Review ST definitions & productsReview ST definitions & products

• Discuss the prevalence of ST useDiscuss the prevalence of ST use

• Describe ST pharmacologyDescribe ST pharmacology

• Discuss ST dependence measures and Discuss ST dependence measures and withdrawalwithdrawal

• Review recommended treatments for ST useReview recommended treatments for ST use